Related Experiment Video
Updated: Jun 11, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Abstract:
Patients with MM have a high risk of VTE. The relationship between MM and ATE is less clear. In this issue of Blood, Libourel and colleagues report a high incidence of ATE in MM patients undergoing chemotherapy.
Insights
Multiple myeloma patients face a high risk of venous thromboembolism (VTE). A new study reveals a significant incidence of arterial thromboembolism (ATE) in these patients during chemotherapy.
Area of Science:
- Hematology
- Oncology
- Cardiovascular Medicine
Background:
- Multiple myeloma (MM) is associated with an elevated risk of venous thromboembolism (VTE).
- The association between MM and arterial thromboembolism (ATE) remains less understood.
- Chemotherapy regimens for MM can influence thrombotic risk.
Discussion:
- This study investigates the incidence of ATE in MM patients undergoing chemotherapy.
- Findings highlight a potentially underestimated risk of ATE in this patient population.
- Understanding the mechanisms linking MM, chemotherapy, and ATE is crucial.
Key Insights:
- Multiple myeloma patients undergoing chemotherapy exhibit a high incidence of arterial thromboembolism (ATE).
- This contrasts with the more established risk of venous thromboembolism (VTE) in MM.
- The findings necessitate a re-evaluation of thrombotic risk assessment in MM patients.
Outlook:
- Further research is warranted to elucidate the specific pathways contributing to ATE in MM.
- Clinical guidelines may need revision to incorporate ATE risk stratification for MM patients.
- Investigating prophylactic strategies against ATE in this cohort is essential.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Peripheral Artery Disease I: Introduction
